Great Point Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

Great Point Partners’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,128,499	Closed	-$44.7M	–	42
2024 Q1	$44.7M	Sell	1,128,499 -2,574,934	-70%	-$76M	6.97%	2
2023 Q4	$70.6M	Buy	3,703,433 +624,800	+20%	+$8.68M	12.03%	1
2023 Q3	$35.3M	Sell	3,078,633 -285,055	-8%	-$3.51M	6.42%	2
2023 Q2	$34.6M	Sell	3,363,688 -377,073	-10%	-$3.4M	6.77%	1
2023 Q1	$28.9M	Buy	3,740,761 +103,043	+3%	+$821K	5.67%	3
2022 Q4	$26.7M	Buy	3,637,718 +189,197	+5%	+$1.21M	5.24%	4
2022 Q3	$24.8M	Buy	3,448,521 +2,909,702	+540%	+$24M	5.98%	4
2022 Q2	$4.58M	Buy	+538,819	New	+$4.64M	1.1%	30

Great Point Partners's ALPN Position: Q2 2024 in Review

Great Point Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 1,128,499 shares — an estimated $44.7M sold.

Great Point Partners first reported a position in ALPN in Q2 2022 and held it in 8 quarters. The position peaked at $70.6M in Q4 2023. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

Great Point Partners reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
Great Point Partners sold 1,128,499 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $44.7M.
Great Point Partners first reported a position in Alpine Immune Sciences Inc in Q2 2022 and held it in 8 quarters.
Great Point Partners's Alpine Immune Sciences Inc position peaked at $70.6M in Q4 2023.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Great Point Partners's 13F filing for Q2 2024, filed 14 Aug 2024.